As a typical representative of biological DMARDs, Tocilizumab (TCZ) has been a success for the therapy of RA in clinic by specifically inhibiting the receptors of cytokine interleukin-6 (IL-6R) [7]. The gene discussed is IL6R; the disease is rheumatoid arthritis.